444 related articles for article (PubMed ID: 22665726)
1. The role of endogenous antiradical protective system in multiple sclerosis.
Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS.
Huber AK; Wang L; Han P; Zhang X; Ekholm S; Srinivasan A; Irani DN; Segal BM
Neurology; 2014 Oct; 83(17):1500-7. PubMed ID: 25253754
[TBL] [Abstract][Full Text] [Related]
3. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal IgM index correlates with a severe disease course in multiple sclerosis: Clinical and MRI results.
Ozakbas S; Cinar BP; Özcelik P; Baser H; Kosehasanoğullari G
Clin Neurol Neurosurg; 2017 Sep; 160():27-29. PubMed ID: 28622533
[TBL] [Abstract][Full Text] [Related]
5. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alfa and interleukin-4 in cerbrospinal fluid and plasma in different clinical forms of multiple sclerosis.
Obradović D; Kataranovski M; Dincić E; Obradović S; Colić M
Vojnosanit Pregl; 2012 Feb; 69(2):151-6. PubMed ID: 22500369
[TBL] [Abstract][Full Text] [Related]
7. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
[TBL] [Abstract][Full Text] [Related]
8. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
[TBL] [Abstract][Full Text] [Related]
9. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
[TBL] [Abstract][Full Text] [Related]
10. A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis.
Muris AH; Rolf L; Broen K; Hupperts R; Damoiseaux J; Smolders J
J Steroid Biochem Mol Biol; 2016 Nov; 164():254-257. PubMed ID: 26598277
[TBL] [Abstract][Full Text] [Related]
11. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
12. Cytokine profile in relapsing‑remitting multiple sclerosis patients and the association between progression and activity of the disease.
Kallaur AP; Oliveira SR; Colado Simão AN; Delicato de Almeida ER; Kaminami Morimoto H; Lopes J; de Carvalho Jennings Pereira WL; Marques Andrade R; Muliterno Pelegrino L; Donizete Borelli S; Kaimen-Maciel DR; Reiche EM
Mol Med Rep; 2013 Mar; 7(3):1010-20. PubMed ID: 23292766
[TBL] [Abstract][Full Text] [Related]
13. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis.
Calabrese M; Rocca MA; Atzori M; Mattisi I; Favaretto A; Perini P; Gallo P; Filippi M
Ann Neurol; 2010 Mar; 67(3):376-83. PubMed ID: 20373349
[TBL] [Abstract][Full Text] [Related]
14. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
[TBL] [Abstract][Full Text] [Related]
15. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
16. Continuous diffuse brain atrophy independent of relapse as a hallmark of multiple sclerosis beginning from relapsing-remitting stage.
Akaishi T; Fujimori J; Yokote H; Nakashima I
Clin Neurol Neurosurg; 2024 Jul; 242():108342. PubMed ID: 38772279
[TBL] [Abstract][Full Text] [Related]
17. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.
Samson RS; Cardoso MJ; Muhlert N; Sethi V; Wheeler-Kingshott CA; Ron M; Ourselin S; Miller DH; Chard DT
Mult Scler; 2014 Sep; 20(10):1322-30. PubMed ID: 24552746
[TBL] [Abstract][Full Text] [Related]
18. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
[TBL] [Abstract][Full Text] [Related]
19. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy.
Elovaara I; Ukkonen M; Leppäkynnäs M; Lehtimäki T; Luomala M; Peltola J; Dastidar P
Arch Neurol; 2000 Apr; 57(4):546-51. PubMed ID: 10768630
[TBL] [Abstract][Full Text] [Related]
20. Soluble thrombomodulin levels in plasma of multiple sclerosis patients and their implication.
Festoff BW; Li C; Woodhams B; Lynch S
J Neurol Sci; 2012 Dec; 323(1-2):61-5. PubMed ID: 22967748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
